PDS Biotechnology Corp PDSB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
PDS Biotech Reports Third Quarter 2026 Financial Results
PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks
Trading Information
- Previous Close Price
- $0.81
- Day Range
- $0.77–0.85
- 52-Week Range
- $0.20–1.79
- Bid/Ask
- $0.78 / $0.79
- Shares Outstanding
- 122.70M
- Market Cap
- $95.39M
- Volume/Avg
- 3M / 25M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.pdsbiotech.com
Valuation
Metric | PDSB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PDSB
Financial Strength
Metric | PDSB |
|---|---|
Quick Ratio | 3.00 |
Current Ratio | 3.62 |
Interest Coverage | −3.52 |
Quick Ratio
PDSB
Profitability
Metric | PDSB |
|---|---|
Return on Assets (Normalized) | −101.85% |
Return on Equity (Normalized) | −367.27% |
Return on Invested Capital (Normalized) | −98.03% |
Return on Assets
PDSB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|NW>#?fb | LOCK|mnj$ | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|WvHSMvX | LOCK|mJQ^! | $95B | |||
| Moderna Inc MRNA | LOCK|>M^v#%K | LOCK|xX | $79B | |||
| argenx SE ADR ARGX | LOCK|vj#nh! | LOCK|%m! | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|z$%#D^ | LOCK|z!h | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|rNg%>QJ | LOCK|zSKX | $30B | |||
| Incyte Corp INCY | LOCK|>^TL^N | LOCK|M@W | $23B | |||
| BioNTech SE ADR BNTX | LOCK|^D$#tt? | LOCK|ML | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|@$%?B^ | LOCK|pchQ | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|&#nf&j | LOCK|G! | $15B |